Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2025-12-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物关于部分募集资金账户注销的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the cancellation of certain fundraising special accounts. It details the background of the fundraising, the management of the funds, the signing of regulatory agreements, and the specific accounts that have been closed. The document is relatively short (3166 characters) and focuses on the status and management of fundraising accounts rather than presenting financial statements or detailed financial performance. It does not contain financial data or results but is an update on capital management activities related to fundraising accounts. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-12-24 Chinese
安旭生物股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder's plan to reduce their holdings in the company. It details the shareholder's current holdings, the planned reduction amount, timing, and reasons for the reduction. There is no financial data, earnings information, or management discussion. The document is a formal disclosure of a major shareholder's intention to sell shares, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a report or announcement of a report publication.
2025-11-18 Chinese
安旭生物关于召开2025年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会). It includes information on the meeting time, location, participation method, and contact details. It references the prior release of the 2025 third quarter report but does not contain any actual financial data or analysis itself. The document is short (1489 characters) and serves to inform investors about the upcoming earnings call event rather than presenting the earnings report or transcript. Therefore, it is best classified as an Investor Presentation (IP) since it is a detailed presentation for investors focusing on financial results and interaction, rather than the earnings release (ER) or call transcript (CT).
2025-11-17 Chinese
安旭生物2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年第三季度报告' which translates to '2025 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial performance for the third quarter of 2025. The report includes unaudited financial statements and management assurances about the accuracy and completeness of the quarterly report. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) clearly identifies this as an Interim / Quarterly Report. The document length is over 13,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is 'IR' for Interim / Quarterly Report. 9M 2025
2025-10-30 Chinese
安旭生物关于继续使用超募资金及部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the continued use of over-raised funds and some idle raised funds for cash management. It details the types of cash management products, amounts, approval procedures, risk analysis, and compliance with regulatory requirements. The document is a formal disclosure about the company's financing and capital management activities, specifically about the use of raised funds for cash management purposes. It is not a full financial report, audit report, or earnings release, nor is it a meeting presentation or voting result. It fits the category of Capital/Financing Update (CAP) as it provides updates on the company's fundraising and capital usage activities.
2025-10-30 Chinese
国联民生证券承销保荐有限公司关于杭州安旭生物科技股份有限公司继续使用超募资金及部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a securities underwriting and sponsorship company regarding the continued use of surplus raised funds and some idle raised funds by Hangzhou Anxu Biotechnology Co., Ltd. for cash management. It includes specifics about the raised funds, investment projects, investment products, amounts, terms, risk control measures, board resolutions, and the sponsor's verification opinion. The document references regulatory requirements and approvals but does not contain financial statements or quarterly/yearly financial results. It is a formal verification and opinion report related to the use of raised funds, not a financial report or earnings release. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification disclosure related to fundraising and fund usage, not a standalone audit report or annual/interim report.
2025-10-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.